A0232

Alfuzosin hydrochloride

≥98% (HPLC), solid

• Sinónimos: N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide hydrochloride, Uroxatral hydrochloride
• Fórmula empírica (notación de Hill): C₁₉H₂₇N₅O₄ · HCl
• Número CAS: 81403-68-1
• Peso molecular: 425.91
• NACRES: NA.77
• PubChem Substance ID: 329770590
• UNSPSC Code: 12352200
• MDL number: MFCD00879135
• Assay: ≥98% (HPLC)
• Form: solid
• Storage condition: desiccated

Propiedades

• assay: ≥98% (HPLC)
• form: solid
• storage condition: desiccated
• solubility: DMSO: >10 mg/mL, H₂O: insoluble
• originator: Sanofi Aventis
• SMILES string: Cl.COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3
• InChI: 1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
• InChI key: YTNKWDJILNVLGX-UHFFFAOYSA-N
• Gene Information: human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Descripción

Biochem/physiol Actions

Alfuzosin hydrochloride is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin hydrochloride is an alpha-adrenergic blocker.

Features and Benefits

This compound is featured on the α1-Adrenoceptors and α2-Adrenoceptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves